DUBLIN, Apr. 21, 2017 /PRNewswire/ --
Research and Markets has announced the addition of the "Strategic Trends in Private Equity and Venture Capital Funding for Healthcare" report to their offering.
The report Strategic Trends in Private Equity and Venture Capital Funding for Healthcare provides a comprehensive analysis on emerging investment trends within the healthcare industry. Private equity (PE) and venture capital (VC) funds have been important participants in a wide range of industries for many decades - particularly the healthcare industry.
Completed global healthcare private equity deal values exhibited a negative compound annual growth rate (CAGR) of 11.8% from 2010 to 2015, with 2010 recording a total of $33.9 billion, falling to $18.1 billion by 2015.
In 2007, the total value of completed global healthcare Private Equity deals was USD 66.2Billion. This plummeted by 81% to USD 12.6 Billion in 2008. In 2010, the market showed signs of recovery when deal values reached an aggregate of USD 33.9 Billion, an increase of 170.3% from 2008. However, recent years have witnessed a steady decline, with 2015 and 2014 being the exception. Deal values exhibited a negative compound annual growth rate (CAGR) of 11.8% from 2010 to 2015, with 2015 recording a total of USD 18.1 Billion. Despite the recent uptick, 2015 values were nowhere near pre-crash levels. For example, PE deal values recorded totals of USD 53.6 Billion and USD 66.2 Billion in 2006 and 2007, respectively.
The continued decline in R&D productivity is one of the most important challenges the healthcare industry is facing at a global level. Blockbuster therapies, for example, have become increasingly rare, and many drugs continue to face reimbursement challenges in key markets, resulting in declining revenues for companies.
Key Topics Covered:
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2.1 Overview of Private Equity and Venture Capital
2.2 The Significance of Private Equity and Venture Capital in the Healthcare Industry
2.2.1 The Venture-Backed Healthcare Innovation Model
2.2.2 Critical Factors to Consider when Selecting a Venture Capital Firm
2.2.3 What Are the Types of Private Equity Firms Operating in the Healthcare Industry?
3 Global Trends in Private Equity and Venture Capital Investments in the Healthcare Industry
3.1 Is R&D Productivity in Healthcare Still Declining?
3.2 What is Causing the Increase in the Cost of Bringing Medical Interventions to Market?
3.3 Global Healthcare Private Equity Deal Trends: Volume and Value, 2006-2015
3.4 Regional Healthcare Private Equity Deal Trends: Volume and Value, 2006-2015
3.5 Which Therapy Areas Are Receiving Noteworthy Private Equity Investment?
3.6 Top 10 Healthcare Private Equity Deals, 2015
3.7 Top 10 Healthcare Venture Capital Deals, 2015
3.8 Are New Companies in the Healthcare Industry Living in a Post-VC Era?
3.9 What are the Risks if Investments in the Healthcare Industry Decrease Significantly?
3.10 New Funding and Investment Models Emerging in the Healthcare Industry
3.10.1 The Role of Crowdfunding in Early-Stage Healthcare in the Post-VC Era
4 US Private Equity and Venture Capital Industry Dynamics
4.1 Immediate Aftermath of the 2008 Global Financial Crisis on the Value of Capital Commitments to Private Funds in the US
4.2 Venture Capital Fundraising Trends in the US: Volume and Value of Funds, 2006-2015
4.3 US Venture Capital Investment Trends
4.4 Is Biotechnology Still Playing Second Fiddle to the Software Sector?
4.5 Trends in Seed Stage VC Financing in the US by Volume and Value, 2015
4.6 US Venture-Backed Exits, Volume and Value, 2006-2015
4.7 US Venture-Backed Healthcare Acquisitions 2006-2015
5 Equity Offerings in the Healthcare Sector, Value and Volume, 2006-2015
5.1 US Venture-Backed Initial Public Offerings in Healthcare, 2006-2015
5.2 Company Profiles and Initial Public Offer Details
5.2.1 Axovant Sciences (Stock Symbol: AXON)
5.2.2 NantKwest (Stock Symbol: NK)
5.2.3 Adaptimmune Therapeutics (Stock Symbol: ADAP)
5.2.4 Spark Therapeutics (Stock Symbol: ONCE)
5.2.5 Aimmune Therapeutics (Stock Symbol: AIMT)
5.2.6 Blueprint Medicines (Stock Symbol: BPMC)
5.2.7 RegenxBio (Stock Symbol: RGNX)
5.2.8 ProNAi Therapeutics (Stock Symbol: DNAI)
5.2.9 Seres Therapeutics (Stock Symbol: MCRB)
5.2.10 Global Blood Therapeutics (Stock Symbol: GBT)
6 Private Equity Firms, Company Drill-Downs
6.1 TPG Capital
6.2 The Carlyle Group
6.3 Apax Partners
6.4 KKR & Co
6.5 Warburg Pincus
6.6 Bain Capital Private Equity
7 Venture Capital Firms, Company Drill-Downs
7.1 New Enterprise Associates
7.2 OrbiMed Advisors
7.3 Kleiner Perkins Caufield & Byers
7.4 Flagship Ventures
7.5 Third Rock Ventures
7.6 Versant Ventures
8 Future Outlook
8.1 What Factors will Drive Investment in Healthcare Industry in Coming Years?
8.2 Will New Financing Models Provide Sustainable Growth for Early-Stage Healthcare Companies?
8.3 Which Geographical Markets will Drive Investment in Healthcare in Foreseeable Future?
8.4 How will Venture Capital Firms React to Increasing Competition in Healthcare Sector?
- Adaptimmune Therapeutics
- Aimmune Therapeutics
- Apax Partners
- Axovant Sciences
- Bain Capital Private Equity
- Blueprint Medicines
- Flagship Ventures
- Global Blood Therapeutics
- KKR & Co
- Kleiner Perkins Caufield & Byers
- New Enterprise Associates
- OrbiMed Advisors
- ProNAi Therapeutics
- Seres Therapeutics
- Spark Therapeutics
- TPG Capital
- The Carlyle Group
- Third Rock Ventures
- Versant Ventures
- Warburg Pincus
For more information about this report visit http://www.researchandmarkets.com/research/mcgznj/strategic_trends
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716